EU regulator backs new Alzheimer’s treatment, reversing initial decision to reject it
An expert committee recommended that the drug be offered to a narrow group of patients with early-stage Alzheimer’s disease.
An expert committee recommended that the drug be offered to a narrow group of patients with early-stage Alzheimer’s disease.
What's Your Reaction?
